Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

ut Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.  

Forward Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to expected DIFICID™ increases in the U.S. population over age 65 and the incidence of CDI, DIFICID potential regulatory approval of DIFICID, and the awareness of CDI among healthcare professionals. Words such as "believes," "would," "anticipates," "plans," "expects," "may," "intend," "will," and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the development of alternative treatments for or means of preventing CDI, whether regulatory authorities will review or
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
(Date:7/30/2015)... Edwards Lifesciences Corporation (NYSE: EW ), the global leader ... announced that Robert A. Ingram has retired from ... ardent champion for innovation in the lifesciences industry, and it ... board as we pursue our focused innovation strategy," said ... provided a valuable perspective to our board, drawing on his ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Results from Gene Identification Studies Presented at ASCO Support, ... ... REDWOOD CITY, Calif., May 31 Genomic Health,Inc. (Nasdaq: GHDX ... of two separate studies presented at the annual,meeting of the American ...
... from Phase III clinical trial --, CHICAGO, ... today announced the presentation of updated results from,a ... comparing,VELCADE and dexamethasone (VcD) to vincristine, adriamycin and,dexamethasone ... of,19 percent in the VcD arm as induction ...
Cached Medicine Technology:Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 2Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 3Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 4Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in ... each year is the Super Bowl. In the two weeks that separate the conference championships ... venue. The 2016 Super Bowl game will mark the 50th time it has been held ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... industry players to know in predictive health analytics , Jvion continues to ... The firm creates predictive software that targets patient and population level illness to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, ... Inc. has re-branded their social media profiles to better connect with the public. ... to communicate, find information, share insights and opinions. The Rally Insurance Group, Inc.’s ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... Ticket ... Theatre . Those looking to catch a new and refreshing show on Broadway, ... numerous awards and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... Thompson HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay ... ranging from crushing depression and crippling anxiety to powerful delusions ... real from the imagined. And if that weren,t enough, ... of the world perceives their inner struggle. Stigma ...
... , THURSDAY, Dec. 29 (HealthDay News) -- Individuals may ... if they carry abnormalities in the so-called "ATM" gene, ... upcoming issue of Cancer Discovery , stems from ... comparative purposes, 190 other individuals who did not have ...
... Dec. 29, 2011--Dr. Andrew Advani, an endocrinologist at St. ... America who received a newly created Novo Nordisk Diabetes ... worth $325,000 (U.S.) over two years. His research ... in patients suffering from diabetes. In diabetic kidney disease, ...
... HealthDay Reporter , WEDNESDAY, Dec. 28 (HealthDay News) ... and vitamins B, C, D and E in their blood ... tended to have larger brain volume, a new study finds. ... blood fared worse on certain thinking tests than those with ...
... Disease-causing strains of the fungus Fusarium are present ... of infection in humans, according to a new study. ... agricultural crops, but some species of the fungus can cause ... example, Fusarium was the cause of an outbreak ...
... crystal-clear tunes at high volume for hours on end ... according to Tel Aviv University research, these advances have also ... teenagers as the most at-risk group. One ... as a direct result of these listening habits, says Prof. ...
Cached Medicine News:Health News:Even Today, the Stigma of Mental Illness Won't Fade 2Health News:Even Today, the Stigma of Mental Illness Won't Fade 3Health News:Gene Mutation May Be Key to Familial Pancreatic Cancer 2Health News:Vitamins, Omega-3s May Keep Brain From Shrinking: Study 2Health News:Vitamins, Omega-3s May Keep Brain From Shrinking: Study 3Health News:Fungus Found in Sinks Can Cause Serious Infections 2Health News:Turn down the iPod to save your hearing 2
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Regular tip. 1 mm x 13 mm. Serrated. Insulated....
Colibri style with 1.5 mm long angled tip and 0.12 mm teeth. Serrated handles with polished finish....
Straight shafts with 4 mm jaws. Serrated handle with dull finish. Jaws straight....
Medicine Products: